Literature DB >> 19474066

Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa.

Christian G Giske, James Ge, Patrice Nordmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19474066     DOI： 10.1093/jac/dkp193

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

Authors:  Catharine C Bulik; Henry Christensen; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

2.  Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.

Authors:  Bartolomé Moyá; Laura Zamorano; Carlos Juan; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Rachel L Soon; Justin R Lenhard; Zackery P Bulman; Patricia N Holden; Pamela Kelchlin; Judith N Steenbergen; Lawrence V Friedrich; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

4.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

5.  Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; Laura Zamorano; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

6.  Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).

Authors:  David J Farrell; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

7.  Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon G Tomaselli; Donna Nicholls; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

Review 8.  Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.

Authors:  Mai-Chi Hong; Donald I Hsu; Mark Bounthavong
Journal:  Infect Drug Resist       Date:  2013-11-29       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.